metronidazole IV

PreclinicalSmall molecule

metronidazole IV is one of 4 small molecule programs targeting Complicated Appendicitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complicated AppendicitisActive, not recruiting

Complicated AppendicitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Complicated Appendicitis

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Rocephin

CConrado Roberto Hoffmann Filho

Approved

1 3

Antibiotic

Pfizer

Preclinical

1 4

metronidazole IV

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT01407016·6 enrolled

Complicated Appendicitis1 trial

Laparoscopic Appendectomy for Uncomplicated Appendicitis: Does Antimicrobial Prophylaxis Really Matter?

Unknown status·HHaEmek Medical Center, Israel·N/A·NCT02404064·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for metronidazole IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — metronidazole IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for metronidazole IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

metronidazole IV

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Complicated Appendicitis1 trial

References

Drug Info

Quick Facts

Related News